<DOC>
	<DOCNO>NCT00076947</DOCNO>
	<brief_summary>The purpose study determine safety new HIV vaccine . The vaccine study mixed chemical call alum improve body 's response vaccine . Healthy adult infect HIV may participate study .</brief_summary>
	<brief_title>Safety EnvPro HIV Vaccine Healthy Volunteers</brief_title>
	<detailed_description>EnvPro recombinant , purify envelope protein vaccine aluminum hydroxide ( alum ) adjuvant . Aluminum hydroxide license adjuvant vaccine , hepatitis B vaccine . This study examine safety tolerability EnvPro alum adjuvant healthy , HIV uninfected adult . All participant study receive vaccine injection upper arm muscle . Participants receive second vaccine injection eight week first injection . Blood test perform study visit vaccine give , eight week injection , select time three year vaccine give .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>HIV uninfected Normal medical history physical exam Normal complete blood count Normal liver function Normal renal function Normal serum creatine phosphokinase ( CPK ) Availability least 1 year followup History immunosuppressive illness , chronic illness , use immunosuppressive medication Medical psychiatric condition occupational responsibility preclude compliance study Live attenuate vaccine within 60 day study entry Use experimental agent within 30 day study entry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2005</verification_date>
	<keyword>HIV Preventive Vaccine</keyword>
	<keyword>HIV Seronegativity</keyword>
	<keyword>Protein</keyword>
</DOC>